A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic WM: the ASPEN study

Key Findings

• ●VGPR rate 28% zanubrutinib vs 19% ibrutinib (non-significant trend, P=0.09)
• ●Zanubrutinib associated with less cardiovascular toxicity, particularly atrial fibrillation
• ●Both agents highly effective; zanubrutinib better tolerated

Referenced in (1 disease)

No validation events recorded yet. Source will be checked on the next kipine-source-validator run.